Saroglitazar was generally well tolerated, with adverse events balanced between the saroglitazar-treated and placebo-treated groups. Based on these results, Zydus Therapeutics intends to submit a US regulatory application for saroglitazar in the first quarter of 2026. Shares of Zydus Lifesciences Ltd ended at ₹980.75, up by ₹3.85 or 0.39%, on the BSE today (August 29).
